首页> 外文期刊>American Journal of Pathology >Mixed Medullary-Follicular Thyroid Carcinoma : Molecular Evidence for a Dual Origin of Tumor Components
【24h】

Mixed Medullary-Follicular Thyroid Carcinoma : Molecular Evidence for a Dual Origin of Tumor Components

机译:混合型髓样滤泡性甲状腺癌:肿瘤成分双重起源的分子证据

获取原文
获取原文并翻译 | 示例
           

摘要

Mixed medullary-follicular carcinomas (MMFCs) are tumors of the thyroid that display morphological and immunohistochemical features of both medullary and follicular neoplasms. The histogenetic origin and possible molecular mechanisms leading to MMFCs are still unclear. To address these questions, we have isolated the two histological components of 12 MMFCs by (laser-based) microdissection, analyzed them for mutations in the RET proto-oncogene and allelic losses of nine loci on six chromosomes, and studied the clonal composition of MMFCs in female patients. Our results provide strong evidence that the follicular and medullary components in MMFCs are not derived from a single progenitor cell, because the seven tumors amenable for analysis consistently exhibited a different pattern of mutations, allelic losses, and clonal composition. We also demonstrate that follicular structures in MMFCs are often oligo/polyclonal and more frequently exhibit hyperplastic than neoplastic histological features, indicating that at least a subset of MMFCs are composed of a medullary thyroid carcinoma containing hyperplastic follicles.
机译:混合性髓样滤泡癌(MMFCs)是甲状腺的 肿瘤,表现出髓样和滤泡性肿瘤的形态学特征和免疫组化特征。尚不清楚导致MMFCs的组织遗传学 起源和可能的分子机制。为了解决这些问题,我们通过(基于激光的) 显微切割术分离了 12种MMFC的两个组织学成分,分析了它们在RET原癌基因和中的突变。 等位基因在六个染色体上丢失了9个基因座,并研究了女性患者MMFCs的 克隆组成。我们的结果 提供了有力的证据,表明MMFC中的卵泡和髓样成分 并非源自单个祖细胞,因为 这七个易于分析的肿瘤持续显示 突变,等位基因缺失和克隆组成的不同模式。 我们还证明了MMFC中的卵泡结构通常是oligo / polyclonal和比肿瘤的组织学特征更常表现出增生性,表明MMFC的至少亚类由甲状腺髓样癌组成,甲状腺癌中含有增生的卵泡。 sup>

著录项

  • 来源
    《American Journal of Pathology》 |1999年第5期|00001499-00001509|共11页
  • 作者单位

    From the Department of Biomedical Sciences and Oncology,University of Turin, Turin, Italy;

    From the Department of Biomedical Sciences and Oncology,University of Turin, Turin, Italy;

    the Division of Cell and Molecular Pathology,University of Zürich, Zürich, Switzerland;

    and the Department of Pathology,University of Zürich, Zürich, Switzerland;

    and the Department of Pathology,University of Zürich, Zürich, Switzerland;

    and the Department of Pathology and Laboratory Medicine,Mayo Clinic and Foundation, Rochester, Minnesota;

    and the Department of Pathology and Laboratory Medicine,Mayo Clinic and Foundation, Rochester, Minnesota;

    and the Department of Pathology,University of Zürich, Zürich, Switzerland;

    From the Department of Biomedical Sciences and Oncology,University of Turin, Turin, Italy;

    the Division of Cell and Molecular Pathology,University of Zürich, Zürich, Switzerland|and the Department of Pathology,University of Zürich, Zürich, Switzerland;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号